For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Unani Medicine facilities to be upgraded at Hyderabad, Chennai, Lucknow, Silchar and Bengaluru
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
This is the second US FDA GMP inspection of this facility within one year
Subscribe To Our Newsletter & Stay Updated
